Home/Products /paclitaxel-ip-6mg-polyoxyl-35-castor-oil-ip-527mg-dehydrtes-alcohol-ip-49-7-v-v-260mg-injection

Packlin 260 Injection: Paclitaxel 260 mg - Institutional Volume

Name: Packlin 260: Paclitaxel Injection 260 mg
Brand: Packlin 260 Injection
Rating: 4.8 (150 reviews)

Microtubule Stabilization: The Anti-Cancer Mechanism of Paclitaxel

Primary Indication: First-line and Adjuvant Therapy for Breast and Ovarian Cancer

Supply Chain Advantage: Optimal 260 mg Vial for High-Volume Oncology Centers

Important: Specialized Administration and Pre-medication Protocol

Secure Your Monopoly: Packlin 260 PCD Pharma Franchise in Injectable Oncology

Therapeutic

ENDOCRINOLOGY and Hormonal range

Gastroenterology

General and OTC medicines

Gynecology and Fertility

Hepatology

Hypertension/ Blood Pressure

Nutraceuticals, Multivitamins and Multiminerals

Sedative or Antianxiety

Stimulant

Urology

Packlin 260 injection (Paclitaxel) Institutional Purchasing Guide PDF

Packlin 260 Injection

Composition : Paclitaxel IP 6mg + Polyoxyl 35 Castor oil IP 527mg + Dehydrtes Alcohol IP 49.7% v/v

Dosage Form : Injection

Packaging Type : Vial

Packaging : 260mg

Price : ₹0/-

Please Contact For Best Price

Packlin 260 Injection is a large-volume, intravenous chemotherapy solution containing Paclitaxel , a cornerstone drug in the Taxane class. This large presentation is specifically designed for institutional purchasing, high-dose protocols, and maximizing inventory efficiency in major oncology centers and hospitals.

Mechanism and Impact:Paclitaxel is a cytotoxic agent that acts by stabilizing microtubules, preventing their breakdown and essential restructuring required for cell division. This mechanism leads to the arrest of mitosis and the eventual death of rapidly dividing cancer cells, making it highly effective against aggressive solid tumors.

Key Therapeutic Uses:

Breast Cancer: Used in adjuvant, neoadjuvant, and metastatic settings.
Ovarian Cancer: Standard treatment for advanced ovarian carcinoma.
Non-Small Cell Lung Cancer (NSCLC): Used in combination regimens.
Institutional Efficiency: The large $260 mg$ vial size is critical for optimizing procurement and dispensing in high-volume settings.

We offer an exclusive PCD Pharma Franchise opportunity for Packlin 260 Injection, enabling partners to meet the strong institutional demand for high-volume, reliable oncology injectables at a competitive commercial value.

About the Product

Key Therapeutic Uses:

Breast Cancer: Used in adjuvant, neoadjuvant, and metastatic settings.
Ovarian Cancer: Standard treatment for advanced ovarian carcinoma.
Non-Small Cell Lung Cancer (NSCLC): Used in combination regimens.
Institutional Efficiency: The large $260 mg$ vial size is critical for optimizing procurement and dispensing in high-volume settings.

Hair loss (alopecia) Nausea, vomiting, diarrhea Low blood counts (anemia, leukopenia) Peripheral neuropathy (tingling or numbness) Joint/muscle pain

Metastatic breast cancer Advanced ovarian carcinoma Non-small cell lung cancer (NSCLC) AIDS-related Kaposi’s sarcoma Often used as first-line or second-line therapy, either alone or in combination with other chemotherapeutic agents like cisplatin.

Administered intravenously by trained professionals in a clinical setting. Premedication with corticosteroids, antihistamines, and H2 antagonists is essential to minimize hypersensitivity reactions. Requires close monitoring of blood counts, liver function, and cardiac status.

Store below 25°C, protected from light. Do not freeze. Shake well before use. Keep out of reach of children.